<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="salih-myo" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">salih-myo</book-part-id>
      <title-group>
        <title>Salih Myopathy</title>
        <alt-title alt-title-type="alt-title">Synonym: Early-Onset Myopathy with Fatal Cardiomyopathy</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Carmignac</surname>
            <given-names>Virginie</given-names>
          </name>
          <degrees>PhD</degrees>
          <aff>Equipe G&#x000e9;n&#x000e9;tique des Anomalies du D&#x000e9;veloppement<break/>IFR Sant&#x000e9;-STIC<break/>Universit&#x000e9; de Bourgogne<break/>Dijon, France</aff>
          <email>virginie.carmignac@gmail.com</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Suominen</surname>
            <given-names>Tiina</given-names>
          </name>
          <degrees>MSc</degrees>
          <aff>Tampere Neuromuscular Research Unit<break/>The Folkh&#x000e4;lsan Institute of Genetics and the Department of Medical Genetics<break/>Haartman Institute<break/>University of Helsinki<break/>Helsinki, Finland</aff>
          <email>tiina.suominen@uta.fi</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hackman</surname>
            <given-names>Peter</given-names>
          </name>
          <degrees>PhD</degrees>
          <aff>The Folkh&#x000e4;lsan Institute of Genetics and the Department of Medical Genetics<break/>Haartman Institute<break/>University of Helsinki<break/>Helsinki, Finland</aff>
          <email>peter.hackman@helsinki.fi</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Udd</surname>
            <given-names>Bjarne</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Tampere Neuromuscular Research Unit<break/>The Folkh&#x000e4;lsan Institute of Genetics and the Department of Medical Genetics<break/>Haartman Institute<break/>University of Helsinki<break/>Helsinki, Finland</aff>
          <email>bjarne.udd@pshp.fi</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Salih</surname>
            <given-names>Mustafa A</given-names>
          </name>
          <degrees>MB BS, MPCH, MD, Dr Med Sci, FRCPCH</degrees>
          <aff>Division of Pediatric Neurology<break/>College of Medicine<break/>King Saud University<break/>Riyadh, Saudi Arabia</aff>
          <email>mustafa_salih05@yahoo.com</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>12</day>
          <month>1</month>
          <year>2012</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="scs" document-type="chapter">Saethre-Chotzen Syndrome</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="siod" document-type="chapter">Schimke Immunoosseous Dysplasia</related-object>
      <abstract id="salih-myo.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Salih myopathy is characterized by muscle weakness (manifest during the neonatal period or in early infancy) and delayed motor development; children acquire independent walking between age 20 months and four years. In the first decade of life, global motor performances are stable or tend to improve. Moderate joint and neck contractures and spinal rigidity may start in the first decade but become more obvious in the second decade. Scoliosis develops after age 11 years. Cardiac dysfunction starts between ages five and 16 years, progresses rapidly, and leads to death between ages eight and 20 years, usually from heart rhythm disturbances.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>Diagnosis is based on clinical findings, marginally to moderately increased serum creatine kinase levels, characteristic skeletal muscle histology, and biallelic small frameshift deletions in the exons Mex1 and Mex3 of <italic toggle="yes">TTN</italic>, the only gene in which pathogenic variants are known to cause Salih myopathy.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Care, best provided by a multidisciplinary team, includes stretching exercises and physical therapy; assistive mechanical devices for sitting and ambulation as needed; and appropriate technical aid in educational settings. Treat heart failure and cardiac arrhythmia as soon as they are evident. Cardiac transplantation may be considered for progressive dilated cardiomyopathy and heart failure refractory to medical therapy.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Annual influenza vaccine and other respiratory infection-related immunizations are advised; aggressive treatment of lower respiratory tract infections.</p>
          <p><italic toggle="yes">Surveillance:</italic> Every six months from age five years: cardiac function and rhythm. Annually: respiratory function. As needed: orthopedic complications (foot deformity, joint contractures, and spinal deformity) by clinical examination and x-ray as needed.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Ibuprofen in those with congestive heart failure.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>Salih myopathy is inherited in an autosomal recessive manner. The parents of an affected child are obligate heterozygotes (i.e., carriers of one mutated allele) and are asymptomatic. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal diagnosis for pregnancies at increased risk are possible if the pathogenic variants in the family have been identified.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="salih-myo.Diagnosis">
        <title>Diagnosis</title>
        <sec id="salih-myo.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p>Salih myopathy is characterized clinically by the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Muscle weakness manifesting during the neonatal period or in early infancy</p>
            </list-item>
            <list-item>
              <p>Delayed motor milestones but normal cognitive development</p>
            </list-item>
            <list-item>
              <p>Muscle weakness of limb-girdle distribution, myopathic face, variable degree of ptosis, and relative calf muscle hypertrophy</p>
            </list-item>
            <list-item>
              <p>Development of dilated cardiomyopathy between ages five and 16 years</p>
            </list-item>
            <list-item>
              <p>Major heart rhythm disturbances leading to sudden death before age 20 years</p>
            </list-item>
          </list>
        </sec>
        <sec id="salih-myo.Testing">
          <title>Testing</title>
          <p>
            <bold>Biochemical and electrophysiologic studies</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Serum creatine kinase (CK) is marginally to moderately increased (1.5-7x normal).</p>
            </list-item>
            <list-item>
              <p>Electromyography (EMG) shows myopathic features (low-amplitude polyphasic potentials of short duration).</p>
            </list-item>
            <list-item>
              <p>Nerve conduction studies (NCS) are normal.</p>
            </list-item>
          </list>
          <p><bold>Muscle biopsy.</bold> The following findings help distinguish Salih myopathy from <related-object link-type="booklink" source-id="gene" document-id="cmd-overview" document-type="chapter">congenital muscular dystrophy</related-object> (CMD) and other congenital myopathies.</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Histology</bold> of skeletal muscle reveals a pattern compatible with congenital myopathy (<xref ref-type="fig" rid="salih-myo.F1">Figure 1</xref>): mild variation in fiber size, abundant centrally located nuclei, no increase in connective tissue before age six years, and mild endomysial fibrosis after age six years.</p>
              <p>Oxidative stains reveal multiple small lesions of reduced or absent oxidative activity with poorly defined boundaries.</p>
              <p>Myofibrillar ATpase staining shows remarkable type 1 fiber predominance (&#x0003e;90%). In one individual massive muscle fiber loss was seen in a second biopsy taken at age ten years [<xref ref-type="bibr" rid="salih-myo.REF.carmignac.2007.340">Carmignac et al 2007</xref>].</p>
            </list-item>
            <list-item>
              <p><bold>Immunohistochemistry</bold> of skeletal muscle shows normal expression of dystrophin, laminin &#x003b1;2 chain (merosin), integrin &#x003b1;7, &#x003b1; - and &#x003b2;-dystroglycan, desmin, emerin, and the sarcoglycans &#x003b1; (adhalin), &#x003b2;, &#x003b3;, and &#x003b4;.</p>
            </list-item>
            <list-item>
              <p><bold>Electron microscopy</bold> of skeletal muscle (<xref ref-type="fig" rid="salih-myo.F2">Figure 2</xref>) highlights the &#x0201c;minicore-like&#x0201d; lesions seen on histology and reveals multiple foci of sarcomere disruption and mitochondria depletion.</p>
            </list-item>
          </list>
          <p><bold>Heart muscle biopsies</bold> (taken from two individuals) showed increased interstitial fibrosis compatible with dilated cardiomyopathy [<xref ref-type="bibr" rid="salih-myo.REF.carmignac.2007.340">Carmignac et al 2007</xref>]. Oxidative staining was normal without focal oxidative defects or significant disarray of the cardiomyocyte structure in contrast to the classic observation in hypertrophic cardiomyopathy.</p>
          <p><bold>Electrocardiography (ECG)</bold> is very helpful in signaling the occurrence of cardiac involvement. Left axis deviation (left anterior fascicular block) can be seen as early as age four years (<xref ref-type="fig" rid="salih-myo.F3">Figure 3</xref>). With the onset of dilated cardiomyopathy (between ages 5 and 16 years), major rhythm disturbances become evident on ECG and Holter monitoring, including polymorphic premature ventricular complexes, bigeminism and trigeminism, couplets, triplets, atrioventricular heart block, atrioventricular nodal reentrant tachycardia, premature atrial complexes, premature ventricular complexes, and ventricular tachycardia.</p>
          <p><bold>Echocardiogram</bold> reveals, at the onset of cardiomyopathy, reduced function of the left ventricle and dilatation and global hypokinesia without wall hypertrophy. Later, dilatation involves the left atrium and ventricle, subsequently affecting all chambers leading to congestive heart failure.</p>
          <p><bold>Radionuclide angiography</bold> using MUGA (<italic toggle="yes">mu</italic>lti-<italic toggle="yes">g</italic>ated <italic toggle="yes">a</italic>cquisition) scan reveals the deteriorating ventricular function with reduction of the left ventricular ejection fraction (LVEF) followed by reduction of the right ventricle ejection fraction.</p>
          <p><bold>Respiratory function tests</bold> show a moderate restrictive pattern without clinical symptoms.</p>
          <sec id="salih-myo.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing</title>
            <p><bold>Gene.</bold> Salih myopathy is caused by biallelic pathogenic variants in the <italic toggle="yes">TTN</italic> exons (designated Mex1 and Mex3) that encode part of the C-terminal domain of titin.</p>
            <p>Note: The part of the TTN protein that spans the sarcomere M-line is encoded by six exons that have been termed Mex1-Mex6 for &#x02018;M-line exons 1 through 6&#x02019;; these correspond to the last six exons, numbers 358 to 363.</p>
            <p>
              <bold>Clinical testing</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Sequence analysis of select exons</bold>. To date, biallelic pathogenic variants reported to cause Salih myopathy are small frameshift deletions in <italic toggle="yes">TTN</italic> exons Mex1 and Mex3 in consanguineous families of Moroccan and Sudanese origin [<xref ref-type="bibr" rid="salih-myo.REF.carmignac.2007.340">Carmignac et al 2007</xref>] (<xref ref-type="table" rid="salih-myo.T.selected_ttn_pathogenic_vari">Table 2</xref>).</p>
              </list-item>
              <list-item>
                <p>Sequence analysis of other coding regions of <italic toggle="yes">TTN</italic> or deletion/duplication analysis is likely to increase the pathogenic variant detection frequency (see <xref ref-type="sec" rid="salih-myo.Testing_Strategy">Testing Strategy</xref>).</p>
              </list-item>
            </list>
            <table-wrap id="salih-myo.T.summary_of_molecular_genetic" orientation="portrait" position="anchor">
              <label>Table 1. </label>
              <caption>
                <p>Summary of Molecular Genetic Testing Used in Salih Myopathy</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_salih-myo.T.summary_of_molecular_genetic_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_salih-myo.T.summary_of_molecular_genetic_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                    <th id="hd_h_salih-myo.T.summary_of_molecular_genetic_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variants Detected&#x000a0;<sup>2</sup></th>
                    <th id="hd_h_salih-myo.T.summary_of_molecular_genetic_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant Detection Frequency by Test Method&#x000a0;<sup>3</sup></th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_salih-myo.T.summary_of_molecular_genetic_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">TTN</italic>
                    </td>
                    <td headers="hd_h_salih-myo.T.summary_of_molecular_genetic_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis of select exons&#x000a0;<sup>4,&#x000a0;5</sup></td>
                    <td headers="hd_h_salih-myo.T.summary_of_molecular_genetic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Exons Mex1 and Mex3&#x000a0;<sup>6</sup></td>
                    <td headers="hd_h_salih-myo.T.summary_of_molecular_genetic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">~100%</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_salih-myo.T.summary_of_molecular_genetic_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Sequence analysis of all 363 exons&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_salih-myo.T.summary_of_molecular_genetic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Sequence variants</td>
                    <td headers="hd_h_salih-myo.T.summary_of_molecular_genetic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">~100%</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_salih-myo.T.summary_of_molecular_genetic_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>7</sup></td>
                    <td headers="hd_h_salih-myo.T.summary_of_molecular_genetic_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Exon or whole-gene deletions</td>
                    <td headers="hd_h_salih-myo.T.summary_of_molecular_genetic_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Unknown, none reported</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="salih-myo.TF.1.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="salih-myo" object-id="salih-myo.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
                </fn>
                <fn id="salih-myo.TF.1.2">
                  <label>2. </label>
                  <p>See <xref ref-type="sec" rid="salih-myo.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
                </fn>
                <fn id="salih-myo.TF.1.3">
                  <label>3. </label>
                  <p>The ability of the test method used to detect a pathogenic variant that is present in the indicated gene</p>
                </fn>
                <fn id="salih-myo.TF.1.4">
                  <label>4. </label>
                  <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="salih-myo.TF.1.5">
                  <label>5. </label>
                  <p>Exons sequenced may vary by laboratory.</p>
                </fn>
                <fn id="salih-myo.TF.1.6">
                  <label>6. </label>
                  <p>The two pathogenic variants reported to date are in these exons; see <xref ref-type="sec" rid="salih-myo.Molecular_Genetics">Molecular Genetics</xref>.</p>
                </fn>
                <fn id="salih-myo.TF.1.7">
                  <label>7. </label>
                  <p>Testing that identifies exon or whole-gene deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA; included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
        </sec>
        <sec id="salih-myo.Testing_Strategy">
          <title>Testing Strategy</title>
          <p>
            <bold>To confirm/establish the diagnosis in a proband</bold>
          </p>
          <p><bold>Clinical findings</bold> that should be present to warrant consideration of skeletal muscle biopsy and molecular genetic testing include:</p>
          <list list-type="bullet">
            <list-item>
              <p>Delayed motor milestones but normal cognitive development;</p>
            </list-item>
            <list-item>
              <p>Muscle weakness of limb-girdle distribution, myopathic face, variable degree of ptosis, and relative calf muscle hypertrophy;</p>
            </list-item>
            <list-item>
              <p>Dilated cardiomyopathy in association with muscle weakness of limb-girdle distribution.</p>
            </list-item>
          </list>
          <p><bold>Skeletal muscle biopsy</bold> is an integral part of the diagnostic evaluation because of the marked clinical overlap within and between congenital myopathies and congenital muscular dystrophy (CMD). Muscle biopsy sections should be examined for histology, histochemistry, immunohistochemistry, and electron microscopy.</p>
          <p>Note: Cardiac muscle biopsy is currently not indicated following the recognition of the disease.</p>
          <p><bold>Molecular genetic testing.</bold> If clinical findings and skeletal muscle biopsy suggest Salih myopathy, perform molecular genetic testing:</p>
          <list list-type="bullet">
            <list-item>
              <p>Perform sequence analysis of select exons (i.e., Mex1-3) first.</p>
            </list-item>
            <list-item>
              <p>If no pathogenic variants are identified (especially in individuals not of Moroccan or Sudanese origin), is it appropriate to sequence the other Mex exons.</p>
            </list-item>
            <list-item>
              <p>If only one frameshift variant is found in Mex1-3, deletion/duplication analysis is recommended to detect a possible deletion of Mex1-6 exons.</p>
            </list-item>
            <list-item>
              <p>If no pathogenic variants are found in Mex1-3, sequence analysis of the entire coding region could be helpful.</p>
            </list-item>
            <list-item>
              <p>If no pathogenic variants have been identified by sequence analysis, deletion/duplication analysis may useful to detect a pathogenic variant (for example, homozygous deletion of several exons [e.g., Mex3-6]).</p>
            </list-item>
          </list>
          <p><bold>Carrier testing for at-risk relatives</bold> requires prior identification of the pathogenic allelic variants in the family.</p>
          <p>Note: Carriers are heterozygotes for this autosomal recessive disorder and are not at risk of developing the disorder.</p>
          <p><bold>Prenatal diagnosis and preimplantation genetic diagnosis (PGD)</bold> for at-risk pregnancies require prior identification of the pathogenic variants in the family.</p>
        </sec>
      </sec>
      <sec id="salih-myo.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="salih-myo.Clinical_Description">
          <title>Clinical Description</title>
          <p>Salih myopathy is characterized by muscle weakness manifest during the neonatal period or in early infancy, and delayed motor development. Children acquire independent walking between age 20 months and four years. In the first decade of life, global motor performances are stable or tend to improve. During this period skeletal muscle involvement mainly manifests as difficulty in running, climbing stairs, and rising up from the sitting position. Those who survive childhood remain ambulant, with or without support, and maintain normal cognitive function.</p>
          <p>Moderate joint and neck contractures and spinal rigidity may start in the first decade but become more obvious in the second decade. Scoliosis develops after age 11 years.</p>
          <p>Cardiac dysfunction starts between age five and 16 years, progresses rapidly, and leads to death between ages eight and 20 years. Heart rhythm disturbances are the major cause of sudden death and their frequency and severity suggest primary involvement of the conduction system.</p>
          <p>In contrast to individuals with heterozygous pathogenic variants in <italic toggle="yes">TTN</italic> associated with <related-object link-type="booklink" source-id="gene" document-id="udd" document-type="chapter">Udd distal myopathy</related-object>, the parents of individuals with Salih myopathy are heterozygous carriers of a <italic toggle="yes">TTN</italic> pathogenic variant and remain asymptomatic with no cardiac or muscle disorder (<xref ref-type="fig" rid="salih-myo.F4">Figure 4</xref>).</p>
        </sec>
        <sec id="salih-myo.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>No genotype-phenotype correlations are known.</p>
        </sec>
        <sec id="salih-myo.Nomenclature">
          <title>Nomenclature</title>
          <p>Salih myopathy was initially referred to as Salih congenital muscular dystrophy [<xref ref-type="bibr" rid="salih-myo.REF.salih.1998.289">Salih et al 1998</xref>, <xref ref-type="bibr" rid="salih-myo.REF.subahi.2001.297">Subahi 2001</xref>]. Subsequently, it was renamed Salih myopathy [<xref ref-type="bibr" rid="salih-myo.REF.fukuzawa.2008.1841">Fukuzawa et al 2008</xref>, <xref ref-type="bibr" rid="salih-myo.REF.pernigo.2010.2908">Pernigo et al 2010</xref>].</p>
        </sec>
        <sec id="salih-myo.Prevalence">
          <title>Prevalence</title>
          <p>Salih myopathy is thought to be rare. It has been described in consanguineous families of Arab descent originating from Sudan and Morocco. Actual prevalence figures are unknown.</p>
        </sec>
      </sec>
      <sec id="salih-myo.Genetically_Related_Allelic_Di">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>The following are phenotypes known to be associated with mutation of <italic toggle="yes">TTN</italic>:</p>
        <p>
          <bold>Autosomal dominant</bold>
        </p>
        <list list-type="bullet">
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="hyper-card" document-type="chapter">Hypertrophic cardiomyopathy</related-object> (HCM)</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="dcm-ov" document-type="chapter">Dilated cardiomyopathy</related-object> (DCM)</p>
          </list-item>
          <list-item>
            <p>
              <related-object link-type="booklink" source-id="gene" document-id="udd" document-type="chapter">Udd distal myopathy</related-object>
            </p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="hmerf" document-type="chapter">Hereditary myopathy with early respiratory failure</related-object> (HMERF)</p>
          </list-item>
        </list>
        <p><bold>Autosomal recessive.</bold>
<related-object link-type="booklink" source-id="gene" document-id="lgmd-overview" document-type="chapter">Limb-girdle muscular dystrophy type 2J</related-object></p>
      </sec>
      <sec id="salih-myo.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Features of Salih myopathy distinguish it from other early-onset muscle disorders:</p>
        <p><related-object link-type="booklink" source-id="gene" document-id="sma" document-type="chapter"><bold>Spinal muscular atrophy</bold></related-object>
<bold>(SMA),</bold> characterized by progressive symmetric muscle weakness resulting from degeneration and loss of anterior horn cells in the spinal cord and brain stem, is a common cause of muscle weakness in the neonatal period or early infancy [<xref ref-type="bibr" rid="salih-myo.REF.salih.a">Salih 2012a</xref>]. Shared features of SMA and Salih myopathy:</p>
        <list list-type="bullet">
          <list-item>
            <p>Early onset of muscle weakness (age 6-12 months) (SMA II)</p>
          </list-item>
          <list-item>
            <p>Weakness resulting in frequent falling and difficulty in walking up and down stairs (SMA III)</p>
          </list-item>
          <list-item>
            <p>Normal intelligence</p>
          </list-item>
        </list>
        <p>Features of SMA that distinguish it from Salih myopathy:</p>
        <list list-type="bullet">
          <list-item>
            <p>Onset after age 12 months (SMA III)</p>
          </list-item>
          <list-item>
            <p>Frequent finger trembling</p>
          </list-item>
          <list-item>
            <p>Sparing of facial muscles</p>
          </list-item>
          <list-item>
            <p>Serum CK: normal</p>
          </list-item>
          <list-item>
            <p>ECG: frequent background tremors (reflecting the spontaneous motor unit activity) but absence of cardiac involvement [<xref ref-type="bibr" rid="salih-myo.REF.salih.b">Salih 2012b</xref>]</p>
          </list-item>
          <list-item>
            <p>EMG: neurogenic features (polyphasic waves, positive sharp waves and fibrillations) as opposed to myopathic EMG features seen in Salih myopathy.</p>
          </list-item>
          <list-item>
            <p>Skeletal muscle histology: group atrophy of type 1 and type 2 muscle fibers (in contrast with type 1 fiber predominance seen in Salih myopathy)</p>
          </list-item>
        </list>
        <p><related-object link-type="booklink" source-id="gene" document-id="dbmd" document-type="chapter"><bold>Duchenne muscular dystrophy</bold></related-object>
<bold>(DMD)</bold> usually manifests in early childhood with delayed milestones. Subclinical or clinical cardiac involvement presents in the majority of affected individuals. Features of DMD that distinguish it from Salih myopathy:</p>
        <list list-type="bullet">
          <list-item>
            <p>Serum CK: high (&#x0003e;10-300x normal)</p>
          </list-item>
          <list-item>
            <p>ECG: characteristic pattern</p>
          </list-item>
          <list-item>
            <p>Skeletal muscle histology: established dystrophic morphology seen early in childhood</p>
          </list-item>
          <list-item>
            <p>Immunohistochemical staining of skeletal muscle: negative for dystrophin</p>
          </list-item>
        </list>
        <p><bold>Sarcoglycanopathies</bold> are common in North Africa and the Arabian Peninsula, where Salih myopathy originated [<xref ref-type="bibr" rid="salih-myo.REF.salih.2010">Salih 2010</xref>]. Overlapping features of the sarcoglycanopathies and Salih myopathy:</p>
        <list list-type="bullet">
          <list-item>
            <p>Onset between ages three and 15 years</p>
          </list-item>
          <list-item>
            <p>In some, delayed walking and frequent falling [<xref ref-type="bibr" rid="salih-myo.REF.boyden.2010.449">Boyden et al 2010</xref>]</p>
          </list-item>
          <list-item>
            <p>Cardiomyopathy (see <related-object link-type="booklink" source-id="gene" document-id="lgmd-overview" document-type="chapter">Limb-Girdle Muscular Dystrophy Overview</related-object>)</p>
          </list-item>
          <list-item>
            <p>ECG: left anterior fascicular block [<xref ref-type="bibr" rid="salih-myo.REF.subahi.2001.297">Subahi 2001</xref>]</p>
          </list-item>
        </list>
        <p>Features of the sarcoglycanopathies that distinguish them from Salih myopathy:</p>
        <list list-type="bullet">
          <list-item>
            <p>Serum CK: high (10-70x normal)</p>
          </list-item>
          <list-item>
            <p>ECG: tall R wave in V1 and V2 (in contrast to Salih myopathy where deep S waves are seen in the right precordial leads associated with reduced R/S ratio [<xref ref-type="fig" rid="salih-myo.F3">Figure 3</xref>])</p>
          </list-item>
          <list-item>
            <p>Echocardiogram: left ventricular dysfunction associated with regional wall motion abnormalities, (e.g., inferior wall and posterior septum hypokinesia) (in contrast to Salih myopathy, in which the contractile dysfunction and dilatation, initially restricted to the left ventricle, subsequently affects all chambers [<xref ref-type="bibr" rid="salih-myo.REF.carmignac.2007.340">Carmignac et al 2007</xref>])</p>
          </list-item>
          <list-item>
            <p>Skeletal muscle histology: dystrophic early in the course of the disease</p>
          </list-item>
          <list-item>
            <p>Immunohistochemical staining of skeletal muscle: negative staining for one or more of the sarcoglycans &#x003b1; (adhalin), &#x003b2;, &#x003b3;, and &#x003b4;</p>
          </list-item>
        </list>
        <p><bold>Other forms of</bold>
<related-object link-type="booklink" source-id="gene" document-id="lgmd-overview" document-type="chapter"><bold>limb-girdle muscular dystrophy</bold></related-object>
<bold>(LGMD)</bold></p>
        <p><bold>LGMD2I</bold>, caused by pathogenic variants in the fukutin-related protein gene (<italic toggle="yes">FKRP</italic>) [<xref ref-type="bibr" rid="salih-myo.REF.nigro.2011.429">Nigro et al 2011</xref>]<italic toggle="yes">,</italic> shows phenotypic overlap with Salih myopathy:</p>
        <list list-type="bullet">
          <list-item>
            <p>Onset within the first year [<xref ref-type="bibr" rid="salih-myo.REF.boyden.2010.449">Boyden et al 2010</xref>]</p>
          </list-item>
          <list-item>
            <p>In some, development of cardiomyopathy within the first year of life [<xref ref-type="bibr" rid="salih-myo.REF.margeta.2009.883">Margeta et al 2009</xref>]</p>
          </list-item>
          <list-item>
            <p>Presence of muscle weakness and calf muscle hypertrophy</p>
          </list-item>
          <list-item>
            <p>Skeletal muscle histology: in some, mild myopathic features (however, significantly reduced signal with &#x003b1;-dystroglycan on immunostaining)</p>
          </list-item>
        </list>
        <p>Features of LGMD2I that distinguish it from Salih myopathy:</p>
        <list list-type="bullet">
          <list-item>
            <p>Absence of ptosis</p>
          </list-item>
          <list-item>
            <p>Serum CK: elevated</p>
          </list-item>
          <list-item>
            <p>ECG: dysmorphic notched P-waves, complete or incomplete right bundle branch block (BBB) or incomplete left BBB, and Q waves in lateral leads [<xref ref-type="bibr" rid="salih-myo.REF.hermans.2010.479">Hermans et al 2010</xref>]</p>
          </list-item>
        </list>
        <p><bold>LGMD2J</bold>, which is allelic to Salih myopathy and is caused by homozygous mutation of the C terminus of <italic toggle="yes">TTN</italic>, has later onset (1st to early 4th decade). In about half of all reported cases, weakness ultimately involved the distal muscles. Joint contractures have not been associated with LGMD2J [<xref ref-type="bibr" rid="salih-myo.REF.p_nissonbesnier.2010.1200">P&#x000e9;nisson-Besnier et al 2010</xref>] and cardiac abnormalities have not been described [<xref ref-type="bibr" rid="salih-myo.REF.hermans.2010.479">Hermans et al 2010</xref>].</p>
        <p><related-object link-type="booklink" source-id="gene" document-id="cmd-overview" document-type="chapter"><bold>Congenital muscular dystrophy</bold></related-object>
<bold>(CMD).</bold> Muscle weakness in CMD typically begins at birth or in early infancy. Affected children present with delay or arrest of gross motor development. Subtypes of CMD known to be associated with cardiac involvement include the following:</p>
        <p><bold>Dystroglycanopathies</bold>. Dilated cardiomyopathy has been reported in persons with pathogenic variants of <italic toggle="yes">FKRP</italic> and in persons with <related-object link-type="booklink" source-id="gene" document-id="fcmd" document-type="chapter">Fukuyama CMD</related-object>. These disorders are distinguished from Salih myopathy by the presence of:</p>
        <list list-type="bullet">
          <list-item>
            <p>Intellectual disability / epilepsy</p>
          </list-item>
          <list-item>
            <p>Variable eye malformations</p>
          </list-item>
          <list-item>
            <p>Brain MRI: central nervous system malformations</p>
          </list-item>
        </list>
        <p><bold>Laminin &#x003b1;2 deficiency</bold> (also known as MDC1A) results from biallelic mutation of <italic toggle="yes">LAMA2</italic> and is characterized by congenital hypotonia and delayed or arrested motor milestones, progressive diffuse joint contractures, spinal rigidity, and normal cognitive abilities in the majority of affected individuals. Approximately one third of persons with laminin &#x003b1;2 deficiency develop left ventricular dysfunction [<xref ref-type="bibr" rid="salih-myo.REF.wang.2010.1559">Wang et al 2010</xref>]. Similarities to Salih myopathy:</p>
        <list list-type="bullet">
          <list-item>
            <p>Myopathic facies and (in some individuals), calf muscle hypertrophy [<xref ref-type="bibr" rid="salih-myo.REF.jones.2001.649">Jones et al 2001</xref>, <xref ref-type="bibr" rid="salih-myo.REF.quijanoroy.2002.466">Quijano-Roy et al 2002</xref>]</p>
          </list-item>
        </list>
        <p>Differentiating features of laminin &#x003b1;2 deficiency:</p>
        <list list-type="bullet">
          <list-item>
            <p>Brain MRI: diffuse white matter signal abnormalities</p>
          </list-item>
          <list-item>
            <p>Immunohistochemical staining of skeletal muscle: total or partial merosin deficiency</p>
          </list-item>
        </list>
        <p>See <related-object link-type="booklink" source-id="gene" document-id="mdef-cmd" document-type="chapter"><italic toggle="yes">LAMA2</italic>-Related Muscular Dystrophy</related-object>.</p>
        <p><bold>LMNA-related CMD (L-CMD)</bold> is characterized by infantile hypotonia and weakness of axial-cervical muscles. Cardiac involvement is frequent; affected individuals develop dilated cardiomyopathy [<xref ref-type="bibr" rid="salih-myo.REF.quijanoroy.2008.177">Quijano-Roy et al 2008</xref>]. Sudden death, probably secondary to severe ventricular arrhythmia, has been reported in several individuals. L-CMD is distinguished from Salih myopathy by the absence of the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Facial weakness</p>
          </list-item>
          <list-item>
            <p>Ptosis</p>
          </list-item>
          <list-item>
            <p>Muscle pseudohypertrophy</p>
          </list-item>
        </list>
        <p>
          <bold>Other congenital myopathies</bold>
        </p>
        <p>The congenital myopathies are characterized by hypotonia, delayed motor development, proximal weakness, poor muscle bulk, elongated myopathic facies (in many individuals), scoliosis, and foot deformities. Because of the marked clinical overlap among and between congenital myopathies and CMD, the diagnosis rests on muscle histology that shows morphologic changes resulting from disintegration of the sarcomeric Z-disk and myofibrils. Muscle biopsy findings help guide molecular genetic testing.</p>
        <p><related-object link-type="booklink" source-id="gene" document-id="mmd" document-type="chapter"><bold>Classic multiminicore disease</bold></related-object>
<bold>(MmD)</bold> is caused by <italic toggle="yes">SELENON</italic> (<italic toggle="yes">SEPN1</italic>) pathogenic variants [<xref ref-type="bibr" rid="salih-myo.REF.ferreiro.2002a.739">Ferreiro et al 2002a</xref>]. The phenotype of MmD caused by <italic toggle="yes">RYR1</italic> pathogenic variants is usually milder than that caused by pathogenic variants in <italic toggle="yes">SELENON</italic>, and is also associated with hand involvement [<xref ref-type="bibr" rid="salih-myo.REF.ferreiro.2002b.750">Ferreiro et al 2002b</xref>].</p>
        <p>Classic MmD has considerable overlap with Salih myopathy:</p>
        <list list-type="bullet">
          <list-item>
            <p>Neonatal hypotonia and early-onset delayed motor development</p>
          </list-item>
          <list-item>
            <p>Weakness maximally involving the trunk and neck flexors; pelvic and shoulder girdle muscles to a lesser degree</p>
          </list-item>
          <list-item>
            <p>Individuals usually ambulatory</p>
          </list-item>
          <list-item>
            <p>Facial muscle weakness ranging from absent to severe</p>
          </list-item>
          <list-item>
            <p>Serum CK: may be slightly elevated</p>
          </list-item>
          <list-item>
            <p>Skeletal muscle histology: shows common features with Salih myopathy</p>
          </list-item>
          <list-item>
            <p>H&#x00026;E staining: variability in fiber size, increased number of internal nuclei, and normal or mildly increased fat and connective tissue</p>
          </list-item>
          <list-item>
            <p>Myofibrillar ATPase staining: frequently shows type 1 fiber predominance, whereas oxidative stains reveal minicores (multiple focal lesions of sarcomere disruption and/or reduced or absent oxidative activity) (see <xref ref-type="fig" rid="salih-myo.F1">Figure 1</xref>)</p>
          </list-item>
          <list-item>
            <p>Electron microscopy: appearance of the cores ranging from focal areas of Z-line streaming and reduced or absent mitochondria to severe focal disorganization of myofibrillar structure [<xref ref-type="bibr" rid="salih-myo.REF.ferreiro.2000.745">Ferreiro et al 2000</xref>]</p>
          </list-item>
        </list>
        <p>Features of MmD that distinguish it from Salih myopathy:</p>
        <list list-type="bullet">
          <list-item>
            <p>Major respiratory involvement requiring respiratory support</p>
          </list-item>
          <list-item>
            <p>Cardiac involvement (right ventricular failure, cardiomyopathy) secondary to respiratory impairment</p>
          </list-item>
        </list>
      </sec>
      <sec id="salih-myo.Management">
        <title>Management</title>
        <sec id="salih-myo.Evaluations_Following_Initial">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs of an individual diagnosed with Salih myopathy, the following are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Neurologic examination</p>
            </list-item>
            <list-item>
              <p>Assessment of strength and joint mobility by physical and occupational therapists</p>
            </list-item>
            <list-item>
              <p>Assessment of cardiac function with particular attention to possible cardiomyopathy and/or arrhythmia, which are often fatal complications</p>
            </list-item>
            <list-item>
              <p>Comprehensive respiratory evaluation including assessment of respiratory rate and pulmonary function</p>
            </list-item>
            <list-item>
              <p>Spinal x-rays to evaluate for presence of scoliosis in the second decade</p>
            </list-item>
            <list-item>
              <p>Clinical genetics consultation</p>
            </list-item>
          </list>
        </sec>
        <sec id="salih-myo.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Treatment involves prompt management of disease manifestations using a multidisciplinary approach that includes specialists in pediatric neurology, physiotherapy, occupational therapy, orthopedics, cardiology, and pulmonology.</p>
          <p>Stretching exercises and physical therapy help prevent contractures and promote mobility. Assistive mechanical devices including orthotics, canes, and walkers can be used as needed.</p>
          <p>Attention to education by providing school technical aid is important since cognition is normal. Stimulation and emotional support can improve school performance and the sense of social involvement.</p>
          <p>Parents and/or caregivers should be made aware of the symptoms of heart failure, arrhythmia (including presyncope and syncope), and thromboembolic disease, and of the need to urgently seek medical care when any of these symptoms appear.</p>
          <p>Training of caregivers in cardiopulmonary resuscitation may be suggested once the symptoms of cardiomyopathy start.</p>
          <p>Adequate posture should be maintained when lying prone and sitting. Garchois brace (made of plexidur, a rigid but light and heat-deformable material) is used to reduce the degree of deformity and slow the progression of scoliosis [<xref ref-type="bibr" rid="salih-myo.REF.wang.2010.1559">Wang et al 2010</xref>].</p>
          <p>Cardiac transplantation should be considered for progressive dilated cardiomyopathy and heart failure refractory to medical therapy.</p>
        </sec>
        <sec id="salih-myo.Prevention_of_Secondary_Compli">
          <title>Prevention of Secondary Complications</title>
          <p>Annual influenza vaccine and other respiratory infection-related immunizations are advised.</p>
          <p>Lower respiratory tract infections should be treated aggressively when they occur.</p>
        </sec>
        <sec id="salih-myo.Surveillance">
          <title>Surveillance</title>
          <p>Monitor as follows:</p>
          <list list-type="bullet">
            <list-item>
              <p>Every six months: cardiac function (by ECG, 24-hour Holter-ECG recording and echocardiography) starting at age five years.</p>
            </list-item>
            <list-item>
              <p>Yearly: respiratory function, using pulmonary function testing or spirometry.</p>
            </list-item>
            <list-item>
              <p>As needed: orthopedic complications (foot deformity, joint contractures, and spinal deformity) by clinical examination and x-rays as needed.</p>
            </list-item>
          </list>
        </sec>
        <sec id="salih-myo.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Ibuprofen (Brufen<sup>&#x000ae;</sup>):</p>
          <list list-type="bullet">
            <list-item>
              <p>Give with care in those with evidence of cardiomyopathy. A patient who had reduced LVEF developed edema following its administration [Subahi and Salih, unpublished observation]</p>
            </list-item>
            <list-item>
              <p>Avoid in those with congestive heart failure.</p>
            </list-item>
          </list>
        </sec>
        <sec id="salih-myo.Evaluation_of_Relatives_at_Ris">
          <title>Evaluation of Relatives at Risk</title>
          <p>Early diagnosis of at-risk sibs by clinical examination and/or molecular genetic testing is important in order to monitor motor development and cardiac function so that treatment can be instituted early.</p>
          <p>See <xref ref-type="sec" rid="salih-myo.Related_Genetic_Counseling_Iss">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="salih-myo.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>If a fetus is diagnosed prenatally to have Salih myopathy, special considerations are needed at and following delivery since muscle weakness may manifest during the neonatal period.</p>
        </sec>
        <sec id="salih-myo.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ClinicalTrials.gov">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="salih-myo.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="salih-myo.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Salih myopathy is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="salih-myo.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes (i.e., carriers of one mutated allele).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic. Note: In contrast to individuals with heterozygous pathogenic allelic variants in <italic toggle="yes">TTN</italic> associated with Udd distal myopathy, the parents of individuals with Salih myopathy are heterozygous carriers of a <italic toggle="yes">TTN</italic> pathogenic variant and remain asymptomatic with no cardiac or muscle disorder (<xref ref-type="fig" rid="salih-myo.F4">Figure 4</xref>).</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic.</p>
            </list-item>
          </list>
          <p>
            <bold>Offspring of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>No individuals with Salih myopathy have reproduced.</p>
            </list-item>
            <list-item>
              <p>Unless an individual with Salih myopathy has children with an affected individual or a carrier, his/her offspring will be obligate heterozygotes (carriers) for a pathogenic variant in <italic toggle="yes">TTN</italic>.</p>
            </list-item>
          </list>
          <p><bold>Other family members.</bold> Each sib of the proband&#x02019;s parents is at a 50% risk of being a carrier.</p>
        </sec>
        <sec id="salih-myo.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing for at-risk family members is possible if the pathogenic variants in the family have been identified.</p>
        </sec>
        <sec id="salih-myo.Related_Genetic_Counseling_Iss">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="salih-myo.Evaluation_of_Relatives_at_Ris">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="salih-myo.Prenatal_Testing_and_Preimplan">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the pathogenic variants have been identified in an affected family member, prenatal diagnosis for a pregnancy at increased risk and preimplantation genetic diagnosis for Salih myopathy are possible.</p>
        </sec>
      </sec>
      <sec id="salih-myo.Resources">
        <title>Resources</title>
      </sec>
      <sec id="salih-myo.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="salih-myo.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>To date, biallelic pathogenic variants reported to cause Salih myopathy are small frameshift deletions in <italic toggle="yes">TTN</italic> exons Mex1 and Mex3 in consanguineous families of Moroccan and Sudanese origin [<xref ref-type="bibr" rid="salih-myo.REF.carmignac.2007.340">Carmignac et al 2007</xref>]. Carriers of these frameshift variants (i.e. heterozygotes) are asymptomatic, presumably as a result of nonsense-mediated decay (NMD) of the mutated mRNA. Since homozygotes survive, the NMD cannot be complete. Some titin protein that lacks the last C-terminal domains is produced. Whether the total decrease of titin protein or the loss of C-terminus is more important for the phenotype is not known.</p>
          <p><bold>Gene structure.</bold>
<italic toggle="yes">TTN</italic> has 363 exons with a coding capacity of 113,414 bp. <italic toggle="yes">TTN</italic> has a large number of alternative splicing variants, which can result in confusion in exon and nucleotide numbering in the literature [<xref ref-type="bibr" rid="salih-myo.REF.bang.2001.1065">Bang et al 2001</xref>, <xref ref-type="bibr" rid="salih-myo.REF.guo.2010.753675">Guo et al 2010</xref>]. Transcript variant (N2A) <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_133378.4">NM_133378.4</ext-link> is a long transcript with 312 exons that encodes the isoform N2A, the predominant titin isoform in skeletal muscle. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="salih-myo" object-id="salih-myo.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
          <p><bold>Pathogenic variants.</bold> To date, the biallelic variants reported to cause Salih myopathy are small frameshift deletions in <italic toggle="yes">TTN</italic> exons Mex1 and Mex3 in two consanguineous families of Moroccan and Sudanese origin [<xref ref-type="bibr" rid="salih-myo.REF.carmignac.2007.340">Carmignac et al 2007</xref>] (<xref ref-type="table" rid="salih-myo.T.selected_ttn_pathogenic_vari">Table 2</xref>).</p>
          <table-wrap id="salih-myo.T.selected_ttn_pathogenic_vari" orientation="portrait" position="anchor">
            <label>Table 2. </label>
            <caption>
              <p>Selected <italic toggle="yes">TTN</italic> Pathogenic Variants</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_salih-myo.T.selected_ttn_pathogenic_vari_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                  <th id="hd_h_salih-myo.T.selected_ttn_pathogenic_vari_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                  <th id="hd_h_salih-myo.T.selected_ttn_pathogenic_vari_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_salih-myo.T.selected_ttn_pathogenic_vari_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.97820_97827delACCAAGTG<break/>g.289385_289392delACCAAGTG&#x000a0;<sup>2</sup></td>
                  <td headers="hd_h_salih-myo.T.selected_ttn_pathogenic_vari_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gln32608HisfsTer9<break/>(Q33535HRfsTer7)&#x000a0;<sup>2</sup></td>
                  <td headers="hd_h_salih-myo.T.selected_ttn_pathogenic_vari_1_1_1_3" rowspan="2" valign="middle" align="left" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_133378.4">NM_133378.4</ext-link>
<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_596869.4">NP_596869.4</ext-link></td>
                </tr>
                <tr>
                  <td headers="hd_h_salih-myo.T.selected_ttn_pathogenic_vari_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.98867delA<break/>g.289390_289397delA<break/>(291297delA)&#x000a0;<sup>2</sup></td>
                  <td headers="hd_h_salih-myo.T.selected_ttn_pathogenic_vari_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Lys32956ArgfsTer22<break/>(Lys33883ArgfsTer20)&#x000a0;<sup>2</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
              </fn>
              <fn>
                <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
              </fn>
              <fn id="salih-myo.TF.2.1">
                <label>1. </label>
                <p>Variant designation that does not conform to current naming conventions</p>
              </fn>
              <fn id="salih-myo.TF.2.2">
                <label>2. </label>
                <p>Reference sequence: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/AJ277892.2">AJ277892.2</ext-link></p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Normal gene product.</bold> Titin is the biggest single polypeptide in humans, found in numerous isoform size variants. The entire coding region predicts a protein of 38,138 amino acids (4200 kd). Titin is expressed as several different isoforms, caused by alternative splicing, in different skeletal muscles and cardiac muscle [<xref ref-type="bibr" rid="salih-myo.REF.bang.2001.1065">Bang et al 2001</xref>, <xref ref-type="bibr" rid="salih-myo.REF.guo.2010.753675">Guo et al 2010</xref>].</p>
          <p>Titin functions as a template in sarcomere assembly and for maintenance of sarcomere integrity. The titin protein is the third myofilament in the sarcomere along with myosin and actin filaments. Titin spans more than one half the length of a sarcomere in heart and skeletal muscle. Structurally different parts of the protein perform distinct functions (mechanical, developmental, and regulatory) [<xref ref-type="bibr" rid="salih-myo.REF.carmignac.2007.340">Carmignac et al 2007</xref>]. Titin binds and interacts with a large number of other sarcomeric proteins.</p>
          <p><bold>Abnormal gene product.</bold> The predicted truncated titins resulting from the frameshift variants in Mex1 and Mex3 are incorporated into ultrastructurally normal sarcomeres in homozygous affected individuals [<xref ref-type="bibr" rid="salih-myo.REF.carmignac.2007.340">Carmignac et al 2007</xref>]. Therefore, absence of the last five (Mex2-Mex6) exons is compatible with life but causes this severe congenital disorder. Asymptomatic heterozygous carriers of these titin deletions presumably have sufficient full-length titin to result in normal sarcomere function.</p>
        </sec>
      </sec>
      <sec id="salih-myo.References">
        <title>References</title>
        <sec id="salih-myo.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="salih-myo.Literature_Cited.reflist0">
            <ref id="salih-myo.REF.bang.2001.1065">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bang</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Centner</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fornoff</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Geach</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gotthardt</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McNabb</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Witt</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Labeit</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gregorio</surname>
                    <given-names>CC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Granzier</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Labeit</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>The complete gene sequence of titin, expression of an unusual approximately 700-kDa titin isoform, and its interaction with obscurin identify a novel Z-line to I-band linking system.</article-title>
                <source>Circ Res.</source>
                <volume>89</volume>
                <fpage>1065</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">11717165</pub-id>
              </element-citation>
            </ref>
            <ref id="salih-myo.REF.boyden.2010.449">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Boyden</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salih</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duncan</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>White</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Estrella</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burgess</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seidahmed</surname>
                    <given-names>MZ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Jarallah</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alkhalidi</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Maneea</surname>
                    <given-names>WM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bennett</surname>
                    <given-names>RR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alshemmari</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kunkel</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kang</surname>
                    <given-names>PB</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Efficient identification of novel mutations in patients with limb girdle muscular dystrophy.</article-title>
                <source>Neurogenetics.</source>
                <volume>11</volume>
                <fpage>449</fpage>
                <lpage>55</lpage>
                <pub-id pub-id-type="pmid">20623375</pub-id>
              </element-citation>
            </ref>
            <ref id="salih-myo.REF.carmignac.2007.340">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Carmignac</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salih</surname>
                    <given-names>MAM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quijano-Roy</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marchand</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marchand</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al Rayess</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mukhtar</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ja</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Labeit</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guicheney</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leturcq</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gautel</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fardau</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campbell</surname>
                    <given-names>KP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richard</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Estournet</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferreiro</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>C-terminal titin deletions cause a novel early-onset myopathy with fatal cardiomyopathy.</article-title>
                <source>Ann Neurol</source>
                <volume>61</volume>
                <fpage>340</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">17444505</pub-id>
              </element-citation>
            </ref>
            <ref id="salih-myo.REF.ferreiro.2000.745">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ferreiro</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Estournet</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chateau</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romero</surname>
                    <given-names>NB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laroche</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Odent</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toutain</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cabello</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fontan</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>dos Santos</surname>
                    <given-names>HG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haenggeli</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Urtizberea</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guicheney</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fardeau</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Multi-minicore disease--searching for boundaries: phenotype analysis of 38 cases.</article-title>
                <source>Ann Neurol</source>
                <volume>48</volume>
                <fpage>745</fpage>
                <lpage>57</lpage>
                <pub-id pub-id-type="pmid">11079538</pub-id>
              </element-citation>
            </ref>
            <ref id="salih-myo.REF.ferreiro.2002b.750">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ferreiro</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Monnier</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romero</surname>
                    <given-names>NB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leroy</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonnemann</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haenggeli</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Straub</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voss</surname>
                    <given-names>WD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nivoche</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jungbluth</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lemainque</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voit</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lunardi</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fardeau</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guicheney</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2002b</year>
                <article-title>A recessive form of central core disease, transiently presenting as multi-minicore disease, is associated with a homozygous mutation in the ryanodine receptor type 1 gene.</article-title>
                <source>Ann Neurol</source>
                <volume>51</volume>
                <fpage>750</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">12112081</pub-id>
              </element-citation>
            </ref>
            <ref id="salih-myo.REF.ferreiro.2002a.739">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ferreiro</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quijano-Roy</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pichereau</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moghadaszadeh</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goemans</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonnemann</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jungbluth</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Straub</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Villanova</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leroy</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romero</surname>
                    <given-names>NB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muntoni</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Voit</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Estournet</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richard</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fardeau</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guicheney</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2002a</year>
                <article-title>Mutations of the selenoprotein N gene, which is implicated in rigid spine muscular dystrophy, cause the classical phenotype of multiminicore disease: reassessing the nosology of early-onset myopathies</article-title>
                <source>Am J Hum Genet</source>
                <volume>71</volume>
                <fpage>739</fpage>
                <lpage>49</lpage>
                <pub-id pub-id-type="pmid">12192640</pub-id>
              </element-citation>
            </ref>
            <ref id="salih-myo.REF.fukuzawa.2008.1841">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fukuzawa</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lange</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holt</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vichola</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carmignac</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferreiro</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Udd</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gautel</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Interchains with titin and myomesin target obscuring and obscuring-like 1 to the M-band-implication for hereditary myopathies.</article-title>
                <source>J Cell Sci</source>
                <volume>121</volume>
                <fpage>1841</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">18477606</pub-id>
              </element-citation>
            </ref>
            <ref id="salih-myo.REF.guo.2010.753675">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Guo</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bharmal</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Esbona</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greaser</surname>
                    <given-names>ML</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Titin diversity--alternative splicing gone wild.</article-title>
                <source>J Biomed Biotechnol.</source>
                <volume>2010</volume>
                <fpage>753675</fpage>
                <pub-id pub-id-type="pmid">20339475</pub-id>
              </element-citation>
            </ref>
            <ref id="salih-myo.REF.hermans.2010.479">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hermans</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pinto</surname>
                    <given-names>YM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Merkies</surname>
                    <given-names>IS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Die-Smulders</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crijns</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Faber</surname>
                    <given-names>CG</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Hereditary muscular dystrophies and the heart.</article-title>
                <source>Neuromuscul Disord.</source>
                <volume>20</volume>
                <fpage>479</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">20627570</pub-id>
              </element-citation>
            </ref>
            <ref id="salih-myo.REF.jones.2001.649">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jones</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morgan</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnston</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tobias</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ouvrier</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilkinson</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>North</surname>
                    <given-names>KN</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>The expanding phenotype of laminin alpha2 chain (merosin) abnormalities: case series and review.</article-title>
                <source>J Med Genet</source>
                <volume>38</volume>
                <fpage>649</fpage>
                <lpage>57</lpage>
                <pub-id pub-id-type="pmid">11584042</pub-id>
              </element-citation>
            </ref>
            <ref id="salih-myo.REF.margeta.2009.883">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Margeta</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Connolly</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winder</surname>
                    <given-names>TL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pestronk</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moore</surname>
                    <given-names>SA</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Cardiac pathology exceeds skeletal muscle pathology in two cases of limb-girdle muscular dystrophy type 2I.</article-title>
                <source>Muscle Nerve</source>
                <volume>40</volume>
                <fpage>883</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">19705481</pub-id>
              </element-citation>
            </ref>
            <ref id="salih-myo.REF.nigro.2011.429">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nigro</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aurino</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piluso</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Limb girdle muscular dystrophies: update on genetic diagnosis and therapeutic approaches.</article-title>
                <source>Curr Opin Neurol</source>
                <volume>24</volume>
                <fpage>429</fpage>
                <lpage>36</lpage>
                <pub-id pub-id-type="pmid">21825984</pub-id>
              </element-citation>
            </ref>
            <ref id="salih-myo.REF.p_nissonbesnier.2010.1200">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>P&#x000e9;nisson-Besnier</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hackman</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suominen</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sarparanta</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huovinen</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richard-Cr&#x000e9;mieux</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Udd</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Myopathies caused by homozygous titin mutations: LGMD2J and variations of phenotype.</article-title>
                <source>J Neurol Neurosurg Psychiatry</source>
                <volume>81</volume>
                <fpage>1200</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">20571043</pub-id>
              </element-citation>
            </ref>
            <ref id="salih-myo.REF.pernigo.2010.2908">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pernigo</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fukuzawa</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holt</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reif</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Steiner</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gautel</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Structural insight into M-band assembly and mechanics from the titin-obscurin-like-1 complex.</article-title>
                <source>Proc Natl Acad Sci USA</source>
                <volume>107</volume>
                <fpage>2908</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">20133654</pub-id>
              </element-citation>
            </ref>
            <ref id="salih-myo.REF.quijanoroy.2002.466">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Quijano-Roy</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Galan</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferreiro</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cheliout-H&#x000e9;raut</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gray</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fardeau</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barois</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guicheney</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romero</surname>
                    <given-names>NB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Estournet</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Severe progressive form of congenital muscular dystrophy with calf pseudohypertrophy, macroglossia and respiratory insufficiency.</article-title>
                <source>Neuromuscul Disord</source>
                <volume>12</volume>
                <fpage>466</fpage>
                <lpage>75</lpage>
                <pub-id pub-id-type="pmid">12031620</pub-id>
              </element-citation>
            </ref>
            <ref id="salih-myo.REF.quijanoroy.2008.177">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Quijano-Roy</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mbieleu</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>B&#x000f6;nnemann</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jeannet</surname>
                    <given-names>PY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Colomer</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clarke</surname>
                    <given-names>NF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cuisset</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roper</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Meirleir</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D'Amico</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ben Yaou</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nascimento</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barois</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Demay</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferreiro</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sewry</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romero</surname>
                    <given-names>NB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ryan</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muntoni</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guicheney</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richard</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonne</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Estournet</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>De novo LMNA mutations cause a new form of congenital muscular dystrophy.</article-title>
                <source>Ann Neurol</source>
                <volume>64</volume>
                <fpage>177</fpage>
                <lpage>86</lpage>
                <pub-id pub-id-type="pmid">18551513</pub-id>
              </element-citation>
            </ref>
            <ref id="salih-myo.REF.salih.1998.289">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Salih</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al Rayess</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cutshall</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Urtizberca</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Turaiki</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozo</surname>
                    <given-names>CO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Straub</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Akbar</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abid</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andeejani</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campell</surname>
                    <given-names>KP</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>A novel form of familial congenital muscular dystrophy in two adolescents.</article-title>
                <source>Neuropediatrics</source>
                <volume>29</volume>
                <fpage>289</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">10029346</pub-id>
              </element-citation>
            </ref>
            <ref id="salih-myo.REF.salih.a">
              <mixed-citation publication-type="book">Salih MAM. Approach to diagnosis and treatment of a child with motor unit disease. In: Elzouki AY, Stapleton FB, Whitley RJ, Oh W, Nazer H, Harfi HA, eds. <italic toggle="yes">Textbook of Clinical Pediatrics.</italic> 2 ed. New York, NY: Springer-Verlag; 2012a.</mixed-citation>
            </ref>
            <ref id="salih-myo.REF.salih.b">
              <mixed-citation publication-type="book">Salih MAM. Hereditary and acquired myopathies. In: Elzouki AY, Stapleton FB, Whitley RJ, Oh W, Nazer H, Harfi HA, eds. <italic toggle="yes">Textbook of Clinical Pediatrics</italic>, 2 ed. New York, NY: Springer-Verlag; 2012b.</mixed-citation>
            </ref>
            <ref id="salih-myo.REF.salih.2010">
              <mixed-citation publication-type="book">Salih MAM. Muscular dystrophies and myopathies in Arab populations. In: Teebi AS, ed. <italic toggle="yes">Genetic Disorders among Arab Populations.</italic> 2 ed. Heidelberg, Germany: Springer-Verlag; 2010:145-79.</mixed-citation>
            </ref>
            <ref id="salih-myo.REF.subahi.2001.297">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Subahi</surname>
                    <given-names>SA</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Distinguishing cardiac features of a novel form of congenital muscular dystrophy (Salih cmd).</article-title>
                <source>Pediatr Cardiol</source>
                <volume>22</volume>
                <fpage>297</fpage>
                <lpage>301</lpage>
                <pub-id pub-id-type="pmid">11455396</pub-id>
              </element-citation>
            </ref>
            <ref id="salih-myo.REF.wang.2010.1559">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonnemann</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rutkowski</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sejersen</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bellini</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Battista</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Florence</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schara</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schuler</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wahbi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aloysius</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bash</surname>
                    <given-names>RO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>B&#x000e9;roud</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bertini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bushby</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohn</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Connolly</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deconinck</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Desguerre</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eagle</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Estournet-Mathiaud</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferreiro</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fujak</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goemans</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iannaccone</surname>
                    <given-names>ST</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jouinot</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Main</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Melacini</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mueller-Felber</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muntoni</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nelson</surname>
                    <given-names>LL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rahbek</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quijano-Roy</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sewry</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Storhaug</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simonds</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tseng</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vajsar</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vianello</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeller</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Consensus statement on standard of care for congenital muscular dystrophies.</article-title>
                <source>J Child Neurol</source>
                <volume>25</volume>
                <fpage>1559</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">21078917</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="salih-myo.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="salih-myo.Acknowledgments">
          <title>Acknowledgments</title>
          <p>The Authors would like to thank Loida M Sese for secretarial work, and Sayed Taha and Vir Salvador for medical illustration.</p>
        </sec>
        <sec id="salih-myo.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>12 January 2012 (me) Review posted live</p>
            </list-item>
            <list-item>
              <p>28 October 2011 (mas) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec sec-type="figs-and-tables">
        <title/>
        <fig position="float" id="salih-myo.F1" orientation="portrait">
          <label>Figure 1. </label>
          <caption>
            <p>Skeletal muscle histology of two children with Salih myopathy taken at age four years (A and D) and 14 years (B and C). A and D. The early biopsy shows (A) increased fiber size variability, abundant centrally located nuclei (CNLs) but no endomyseal fibrosis or necrosis (Van Gieson&#x02019;s stain; original magnification x250). (D) Type 1 fibers (dark) predominate and type 2 fibers (pale, arrows) are scanty (myofibrillar ATPase [4.3]; original magnification x250). B and C. At age 14 years there is also a remarkable number of CNLs (B), associated with endomyseal fibrosis and few necrotic fibers (arrow) (GT; original magnification x250). (C) Oxidative staining reveals the minicore-like lesions (arrowheads; original magnification x250).</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="salih-myo-Image001" position="anchor" orientation="portrait"/>
        </fig>
        <fig position="float" id="salih-myo.F2" orientation="portrait">
          <label>Figure 2. </label>
          <caption>
            <p>Longitudinal electron microscopy section of skeletal muscle taken at age ten years reveals focal disruptions of sarcomeric structures (arrows), Z-disk abnormalities including focal loss of dark Z-disk material, and early dissolution of I-band filaments [original magnification x6000].</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="salih-myo-Image002" position="anchor" orientation="portrait"/>
        </fig>
        <fig position="float" id="salih-myo.F3" orientation="portrait">
          <label>Figure 3. </label>
          <caption>
            <p>Electrocardiogram at age four years showing left axis deviation (left anterior fascicular block)</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="salih-myo-Image003" position="anchor" orientation="portrait"/>
        </fig>
        <fig position="float" id="salih-myo.F4" orientation="portrait">
          <label>Figure 4. </label>
          <caption>
            <p>Mid-calf muscle MRI of parents of a proband at age (A) 55 years and (B) 44 years were normal and showed no fatty degeneration of the anterior tibial muscles.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="salih-myo-Image004" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
